Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar;17(3):166-175.

Treatment of relapsed/refractory acute lymphoblastic leukemia

Shilpa Paul  1 , Caitlin R Rausch  1 , Patrice E Nasnas  1 , Hagop Kantarjian  1 , Elias J Jabbour  1
Affiliations
  • PMID: 30969955
Review

Treatment of relapsed/refractory acute lymphoblastic leukemia

Shilpa Paul et al. Clin Adv Hematol Oncol. 2019 Mar.

Abstract

Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal outcomes, with survival of less than 6 months, and treatment options in the salvage setting have been limited to conventional cytotoxic chemotherapy with minimal activity. Advances in the development of novel targeted therapies have significantly improved outcomes in R/R ALL. Blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor (CAR) T-cell therapy constitute new treatment modalities that are challenging the historical regimens and paving a new path for treating patients with R/R ALL.

PubMed Disclaimer

MeSH terms